Abstract: A multifunctional polyethylene glycol-based hydrogel that includes a multi-arm polyethylene glycol cross-linking unit covalently bound to at least four multi-arm polyethylene glycol nanocarrier units, wherein each nanocarrier unit includes an agent coupled to the nanocarrier unit and each agent is selected from pH-lowering agents, bioadhesion agents, microbicidal-spermicidal agents, and agents that inhibit free and cell-associated HIV binding, provided that each nanocarrier unit comprises a different agent.

Abstract: Methods of preparing a proteoliposome comprise the step of contacting a liposome with an effective portion of RalBP1 to create a proteoliposome. RalBP1 is effective for the protection and treatment of mammals and the environment against the accumulation of toxic compounds and prevents accumulation of one or more toxic compounds, reduces the concentration of toxic compounds, and protects against further contamination with one or more toxic compounds.

Abstract: Methods of preparing a proteoliposome comprise the step of contacting a liposome with an effective portion of RalBP1 to create a proteoliposome. RalBP1 is effective for the protection and treatment of mammals and the environment against the accumulation of toxic compounds and prevents accumulation of one or more toxic compounds, reduces the concentration of toxic compounds, and protects against further contamination with one or more toxic compounds.

Abstract: The present invention relates to a method of immune activation which is effective for eliciting a non-antigen-specific immune response in a member of the bovine species. The method is particularly effective for protecting a member of the bovine species from infectious disease and treating animals inflicted with infectious disease.

Abstract: The present invention generally relates to the transdermal delivery of various compounds. In some aspects, transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising ergopeptines, triptans, and other compounds, including salts and derivatives of these, and optionally, a hostile biophysical environment and/or a nitric oxide donor. In some cases, the composition may be stabilized using a combination of a stabilization polymer (such as xanthan gum, KELTROL® BT and/or KELTROL® RD), propylene glycol, and a polysorbate surfactant such as Polysorbate 20, which combination unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40° C. (at least about 104° F.), as compared to compositions lacking one or more of these.

Abstract: Methods employing chemiluminescent agents as therapeutically active agents in the treatment of proliferative disorders are disclosed. The chemiluminiscent agents are used in the disclosed method without a therapeutically effective amount of a photosensitizer. Novel chemiluminescent agents having the general formula: are also disclosed, wherein X, Y, Z, R3 and R5-R9 are as defined herein.

Abstract: A medicine delivery system includes an inner capsule containing carotenoids and an outer capsule in which the inner capsule is contained within the outer capsule and the outer capsule containing a therapeutically effective amount of krill oil. In one example, the carotenoids comprise at least S,S?-astaxanthin derived from Haematococcus pluvialis, and one or more of lutein and/or trans-zeaxanthin or meso-zeaxanthin. The medicine delivery system also includes 0.5 to 8 mg of astaxanthin, 2 to 15 mg of lutein and 0.2 to 12 mg of trans-zeaxanthin contained within the inner capsule. In a specific example, the medicine delivery system includes about 4 mg of astaxanthin, about 10 mg of lutein and about 1.2 mg of trans-zeaxanthin contained within the inner capsule.

Abstract: The present invention relates to a pharmaceutical calcium acetate formulation and a process for making the same. In particular, the present invention relates to a calcium acetate capsule formulation comprising granules comprising calcium acetate along with other formulation adjuvants contained within a pharmaceutically acceptable capsule.

Abstract: The present invention relates to a pharmaceutical composition comprising solutions, suspensions of dispersions of inositol, or an isomer thereof, in a vehicle comprising gelatin, glycerol or mixtures thereof.

Abstract: A composition for treatment of urinary tract infection derived primarily from pomegranate and cranberry fruit components is disclosed. The composition may be derived from juices, concentrates, liquid extracts, or powdered extracts, e.g. dehydrated pomegranate juice, of pomegranate and cranberry fruits. The concentration of each of the component (i.e. pomegranate product and cranberry product) in the composition is set such as to achieve optimum synergistic effects by increasing urinary tract anti-adhesion activity.

Abstract: An oral complex composition comprising omega-3 fatty acid esters and HMG-CoA reductase inhibitor, can effectively raise serum HDL level while reducing serum LDL and TG levels and can be used to treat hyperlipidemia owing to its good drug dissolution rate and storage stability with showing no delayed release behavior even after 6 months of accelerated storage.

Abstract: The present disclosure relates to pharmaceutical compositions that are abuse resistant and may also provide controlled release. The present disclosure also relates to the use of pharmaceutical compositions in the treatment of pain.

Abstract: Disclosed in certain embodiments is a solid oral dosage form comprising: (a) an inert tamper resistant core; and (b) a coating surrounding the core, the coating comprising an active agent.

Abstract: In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.

Abstract: The present invention relates to solid orally administrable pharmaceutical administration forms comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide (rivaroxaban, active compound (I)), wherein a partial amount of the active compound (I) is released rapidly and a partial amount is released in a controlled manner (modified, retarded, delayed), and to processes for their preparation, their use as medicaments and their use for the prophylaxis, secondary prophylaxis or treatment of disorders.

Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts.

Abstract: The invention relates to oral pharmaceutical compositions containing flibanserin, methods for the preparation thereof and use thereof as a medicament.

Abstract: The present disclosure is directed to a composition for the sustained-release delivery of an active agent to a target cell of an individual. The compositions disclosed herein comprise of at least one porous particle; at least one polymer; and at least one active agent. In an embodiment, the porous particle comprises a plurality of microscale reservoirs. In an exemplary embodiment, the at least one active agent is covalently linked to the at least one polymer to form a polymer-active agent conjugate, and the polymer-active agent conjugate is contained in the plurality of microscale reservoirs of the porous particle. The present disclosure is also directed to a method of treating a tumor, comprising the step of administering to an individual the composition described supra. Additionally, disclosed herein is a method of eliminating tumor stem cells. Furthermore, there is provided a method of circumventing multi-drug resistance in a tumor cell.

Abstract: Methods for preparing a tricalcium phosphate coarse particle composition are provided. Aspects of the methods include converting an initial tricalcium phosphate particulate composition to hydroxyapatite, sintering the resultant hydroxyapatite to produce a second tricalcium phosphate composition and then mechanically manipulating the second tricalcium phosphate composition to produce a tricalcium phosphate coarse particle composition. The subject methods and compositions produced thereby find use in a variety of applications.

Abstract: Iodine-containing germicidal compositions are disclosed that remain physically stable for extended storage periods with little to no iodine complexing agent being present. The compositions employ a mixture of emollients, such as glycerin and ethoxylanolin, to create a composition that in certain embodiments presents a cloudy or emulsion-like appearance.

Abstract: The present invention is directed to a pharmaceutical composition comprising rebamipide having a mean particle size of less than 500 nm, a dispersing agent, and a viscosity enhancing agent wherein the viscosity enhancing agent has no aggregative action for the rebamipide particles, which is used as a gargle or a liquid preparation for swish and swallow comprising rebamipide for preventing and/or treating stomatitis caused by radiotherapy.

Abstract: The present invention provides a controlled release pharmaceutical composition comprising selective serotonin reuptake inhibitor and a process for preparation thereof. The controlled release pharmaceutical composition comprises: a deposit-core comprising a selective serotonin reuptake inhibitor, one or more controlled release agent(s) and one or more pharmaceutically acceptable excipient(s), a support-platform applied to the deposit-core, a controlled release coating and, an immediate release coating comprising a selective serotonin reuptake inhibitor and one or more pharmaceutically acceptable excipient(s).

Abstract: Dermatological compositions containing, in a physiologically acceptable medium, at least one retinoid, dispersed benzoyl peroxide and at least one gelling agent of the family of the carrageenans, are useful for treating dermatological conditions and afflictions linked to disorders of cell differentiation and/or proliferation and/or keratinization, notably for treating acne vulgaris.

Abstract: A self-assembling nanoparticle drug delivery system for the delivery of various bioactive agents including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the bioactive agent, a lipid layer or lipid/cholesterol layer coat and targeting or facilitating molecules anchored in the lipid layer. A method for construction of the self-assembling nanoparticle drug delivery system is also provided.

Abstract: The disclosure relates to uses of saccharide binding moieties, e.g., lectins for targeting cells, typically cancer stem cells. In certain embodiments, the disclosure relates to conjugates comprising: a) a saccharide binding moiety; b) a polymer; and c) a therapeutic agent; wherein the saccharide binding protein is covalently attached to the polymer.

Abstract: A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

Abstract: This invention discloses new krill oil compositions characterized by having high amounts of phospholipids, astaxanthin esters and/or omega-3 contents. The krill oils are obtained from krill meal using supercritical fluid extraction in a two stage process. Stage 1 removes the neutral lipid by extracting with neat supercritical CO2 or CO2 plus approximately 5% of a co-solvent. Stage 2 extracts the actual krill oils by using supercritical CO2 in combination with approximately 20% ethanol. The krill oil materials obtained are compared with commercially available krill oil and found to be more bioeffective in a number of areas such as anti-inflammation, anti-oxidant effects, improving insulin resistances and improving blood lipid profile.

Abstract: A medicine delivery system includes an inner capsule containing carotenoids and an outer capsule in which the inner capsule is contained within the outer capsule and the outer capsule containing a therapeutically effective amount of krill oil. In one example, the carotenoids comprise at least S, S?-astaxanthin derived from Haematococcus pluvialis, and one or more of lutein and/or trans-zeaxanthin or meso-zeaxanthin. The medicine delivery system also includes 0.5 to 8 mg of astaxanthin, 2 to 15 mg of lutein and 0.2 to 12 mg of trans-zeaxanthin contained within the inner capsule. In a specific example, the medicine delivery system includes about 4 mg of astaxanthin, about 10 mg of lutein and about 1.2 mg of trans-zeaxanthin contained within the inner capsule.

Abstract: The present invention provides novel methods of forming mineralized gelatin carriers from bone. The present invention further provides mineralized gelatin carriers themselves; bone products that include such mineralized gelatin carriers including DBM bone products; and kits that include mineralized gelatin carriers formed from bone. The present invention further provides methods for making DBM bone products, wherein both the DBM and a mineralized gelatin carrier for the DBM are derived independently from a bone lot.

Abstract: Demineralized bone particles are obtained by demineralizing whole bone and thereafter subdividing the demineralized bone to provide the demineralized bone particles.

Abstract: The invention provides compounds of the formula (I): The compounds have activity against cyclin dependent kinases, glycogen synthase kinase and Aurora kinases and are therefore useful to treat cancer and viral diseases.

Abstract: Disclosed herein are methods and composition for alteration of the presence, activity, or concentration of RNF138. Disclosed methods can be utilized to affect DNA double strand break repair. Methods and compositions can be utilized to alter RNF138 so as to prevent interaction between RNF138 and RAD51D. Specifically, methods can prevent RNF138-directed ubiquitylation of RAD51D, which is necessary for DNA double strand break repair.

Abstract: Sustained-released beads providing active ingredients over an extended period of time to an individual orally ingesting the sustained release beads. The sustained-release beads can be part of a suspension wherein the sustained-release beads are suspended and evenly dispersed in the suspension. Binding agents are used to form the structural framework of the sustained released beads and retain the active ingredients without chemical or electrical bonding. The components of the dispersion medium are GRAS designated, making the suspension suitable for use as a food product.

Abstract: The invention provides a colon cleansing solution comprising: a) 300 to 2000 mmol per litre ascorbate anion provided by ascorbic acid, one or more salts of ascorbic acid, or a mixture thereof; and b) 10 to 200 g per litre polyethylene glycol. The invention also provides methods and kits associated with, or making use of the solutions. The invention also provides a method of cleansing the colon of a subject comprising: — administering to the subject an effective amount of a first cleansing solution; and then after a time interval-administering to the subject an effective amount of a second cleansing solution, where in the two cleansing solutions are as described in the specification.

Abstract: In an embodiment of the present invention, a composition for removing a tick and providing relief therefrom comprises a solvent, a carrier fluid suitable for increasing the rate of seepage of the solvent into the host, a solubilizer suitable for increasing the solubility of the composition in water, and a solution that provides soothing and aids in healing the host.

Abstract: The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine ?7 receptor.

Abstract: The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine ?7 receptor.

Abstract: The present invention relates to a pharmaceutical composition for preventing and treating an inflammatory disease, including a mixture of extracts from Trachelospermi Caulis and Paeonia Suffruticosa Andrews as an active ingredient and method for preparing the same. Also, a quasi-drug composition, a health functional food composition and a cosmetic composition, all based on the mixture, are provided for preventing or improving inflammation. In addition, the present invention relates to a method for treating an inflammatory disease by administering the pharmaceutical composition to a subject suspected of having the inflammatory disease. Containing the extract mixture, the composition exhibits excellent anti-inflammatory activity and edema-suppressing activity, compared to individual extracts, and thus can be applied to the prevention, treatment or improvement of an inflammatory disease.

Abstract: The invention relates to a pharmaceutical composition containing active vegetable substances and a mixture made of a polymeric water-soluble and a polymeric water-insoluble matrix forming agent. Said pharmaceutical composition is suitable for the oral administration of active vegetable substances with delayed release.

Abstract: Provided is a novel bleomycin hydrolase production promoter. Provided is a bleomycin hydrolase production promoter, natural moisturizing factor production promoter, and dry skin remedy, comprising as an active ingredient thereof one or a plurality of ingredients selected from the group consisting of chestnut rose extract, angelica root extract, cork tree bark extract, lamium album extract, rosemary extract, benzenesulfonyl GABA and erythritol.

Abstract: The subject invention is based upon the discovery that a wide variety of pharmaceutical agents can be delivered into the skin, fingernails, and toenails of patients by dissolving or dispersing the pharmaceutical agent in a solvent system which is comprised of a combination of an alkyl lactate and Simmondsia chinesis seed oil. The subject invention more specifically discloses a pharmaceutical serum which is comprised of (1) an alkyl lactate, wherein the alkyl group in the alkyl lactate contains from 2 to about 12 carbon atoms, (2) Simmondsia chinesis seed oil, and (3) a pharmaceutical agent. Some representative examples of pharmaceutical agent which can be incorporated into the pharmaceutical serums of this invention include, hormones, growth factors (cytokines), antimicrobials, antibacterials, antibiotics, non-steroidal anti-inflammatory agents, immunodilators, anesthetics, plant extracts, vitamins, corticosteroids, hair growth stimulants, and the like.

Abstract: The invention relates to a curcuminoid composition with enhanced bioavailability derived from fresh turmeric rhizomes and a process for its preparation.

Abstract: A powder press has an upper yoke, a lower yoke, and a tension element that is in effect between the upper yoke and the lower yoke, as well as a die accommodation plate that is guided along the tension elements. The plate can be displaced parallel to the tension element, via a punch that supports itself on the upper yoke or the lower yoke, or to which pressure can be applied. The punch accommodates a die plate provided on an adapter and includes at least a cylinder and/or a piston disposed in the Cylinder, to which hydraulic pressure can be applied in the cylinder. The powder press has a particularly compact construction if the cylinder and/or the piston surrounds a passage opening through the die accommodation plate or through the upper or lower yoke and/or a tension element.

Abstract: A powder press in which seals of cylinder/piston units that can hydraulically activate or apply pressure to additional plates with reference to a die plate, the upper yoke and/or the lower yoke are kept free of powder to the greatest possible extent disposes a cylinder of a cylinder/piston unit facing away from a die plate and/or an additional plate, preferably below the additional plate.

Abstract: A compression-forming system comprising a molten resin mass-feeding device equipped with the holding portions for holding the molten resin masses, a compression-forming machine equipped with the metal molds, and a molten resin mass position detector, wherein said molten resin mass position detector is a temperature sensor, and said temperature sensor measures the temperature of a portion on the outer side of an allowable range in which the molten resin masses are fed to the metal molds, and judges the presence of the molten resin masses on said portion by the temperature of said portion of the metal molds to detect that the molten resin masses are defectively handed over.

Abstract: One embodiment of a method of manufacturing a textured surface may include providing a first thermally stable sheet, printing a pattern of material on the first sheet to form a three-dimensional textured surface, and curing the material, then using said first sheet to impart negative texture into Tedlar faced epoxy composite blanket, which is in turn used to impart texture into a decorative laminate.

Abstract: There is provided a method for manufacturing a three-dimensional shaped object, comprising the steps of: (i) forming a solidified layer by irradiating a predetermined portion of a powder layer with a light beam, thereby allowing sintering of the powder of the predetermined portion or melting and subsequent solidification thereof; and (ii) forming another solidified layer by newly forming a powder layer on the resulting solidified layer, and then irradiating another predetermined portion of the new powder layer with the light beam, the steps (i) and (ii) being repeatedly performed, wherein the three-dimensional shaped object is manufactured such that it has three different solidified portions of high-density, intermediate-density and low-density solidified portions in at least a part of the object, and wherein the intermediate-density solidified portion is formed to be located in a part of a surface of the three-dimensional shaped object.

Abstract: There is provided a molding stack assembly (202) for producing a molded article (214), the molded article (214) including a neck finish (218) which includes a support ledge (222), the molded article (214) suitable for subsequent blow-molding into a final shaped container.

Abstract: A blow mould for containers wherein the mould base comprises a first member (5) and a second member (6) connectable to each other by means of a quick coupling system comprising at least one first connection pin, wherein said second member (6) includes a first slider (13), defining a first sliding direction on a plane orthogonal to the longitudinal axis of the mould and capable of taking an unlocking position and a locking position, said first slider (13) being provided with at least a hole in order to lock the first connection pin when the first slider (13) is in the locking position, and a second slider (16) defining a second sliding direction on said plane, intersecting said first direction; said second slider (16) being slidable along said second direction from a position of mechanical connection with the first slider (13) to a position of releasing from said first slider.

Abstract: A sweep core die device for a throttle body, or other part, has a cover insert and an ej insert that engage leaving voids therein, a ram component entering the voids, and cores connected to the ram component by ball joints and other components for simultaneous movement in several axes within the voids. The cores are mirror image and connect to one end of a mount. The other end of the mount pivotally connects to the ej insert. A shaft pivotally connects to each mount and to a clamp outwardly from the inserts. The clamp moves relative to the two inserts, moves the shafts, and thus rotates the cores inwardly and outwardly through the voids. The cores have the internal shape of the passage through each horn of a finished throttle body or other part. The cores produce passages so fuel attains laminar flow within the part.